Published in Health Business Week, January 19th, 2007
Brecanavir was in phase II clinical development.
Clinical trial investigators have been notified and directed to transition their patients to marketed antiretrovirals, or appropriate treatments available through expanded access programs.
"GSK is dedicated to excellence in the care of individuals with HIV infection, and we will continue our efforts to find effective treatments with improved resistance profiles for these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.